19:11 , May 31, 2019 |  BC Extra  |  Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
13:05 , Mar 13, 2019 |  BC Innovations  |  Distillery Therapeutics

CD36 as a prostate cancer target

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Patient sample, cell culture and mouse studies suggest inhibiting CD36 could help treat prostate cancer. In patients, high tumor expression of CD36 was associated with metastasis and poor relapse-free...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
20:34 , Jul 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria Cell culture and mouse studies suggest inhibiting Plasmodium VP1 could help treat malaria. In P. falciparum- infected human erythrocytes, parasitic knockdown of PV1 decreased the binding of erythrocytes to CD36 , an interaction...
14:58 , Mar 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Spinal cord injury (SCI) Mouse studies suggest inhibiting CD36 could help treat SCI. In a mouse model of SCI, systemic CD36 knockout decreased lesion area and increased locomotor function compared with normal CD36 expression....
07:00 , Mar 17, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Prosaposin (PSAP); CD36 (GPIV); thrombospondin-1 (TSP-1; THBS1)

Cancer INDICATION: Ovarian cancer Patient sample, cell culture and mouse studies suggest a PSAP-derived peptide could help treat CD36-positive ovarian cancer. In three patient-derived CD36-positive ovarian cancer cell lines, the CD36 ligand TSP-1 increased apoptosis...
07:00 , Jun 18, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: MethylC-capture sequencing (MCC-Seq) for large-scale, epigenome-wide study of methylation status

Biomarkers TECHNOLOGY: Gene profiling MCC-Seq could facilitate large-scale epigenetic studies to identify associations between DNA methylation and disease. Current methods of mapping gene methylation status are biased toward CpG-rich promoter regions, where methylation levels vary...
08:00 , Mar 5, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: CD36 (GPIV); macrophage scavenger receptor 1 (MSR-1; SR-A; CD204)

Cardiovascular disease INDICATION: Atherosclerosis In vitro and mouse studies suggest sugar-based amphiphilic nanoparticles could help treat atherosclerosis. Macrophage recruitment and oxidized low-density lipoprotein (LDL) uptake via scavenger receptors such as CD36 and MSR-1 contributes to...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Company News

University of Montreal, AmorChem deal

The University of Montreal granted VC fund AmorChem exclusive, worldwide rights to a program targeting CD36 (GPIV) to treat atherosclerosis. AmorChem, which invested an undisclosed amount in the program, said it plans to validate lead...
07:00 , May 29, 2014 |  BC Innovations  |  Targets & Mechanisms

S100A9-clot not, bleed not

Although the new generation of antithrombotic drugs provides marked improvements over warfarin, they all still carry bleeding risk. S100 calcium binding protein A9 could represent a new target that, when blocked, prevents thrombosis without increasing...